Swedish Orphan Biovitrum AB (BIOVF) reports robust revenue growth driven by haematology, while facing challenges in immunology and strategic market expansions.

AstraZeneca reports mixed first-quarter 2025 results. The fall in pre-market is likely due to the soft sales performance of ...

On Tuesday, 1827 stocks advanced, 2098 declined and 129 remained unchanged on Bombay Stock Exchange with advance decline ...

Investing.com -- Swedish Orphan Biovitrum shares climbed 3% as the company reported a first-quarter revenue of SEK 6.45 billion marking a 3% increase YoY and surpassing consensus expectations by the ...

Dr Reddy’s Laboratories on Monday said it has expanded its strategic partnership with French biopharma giant Sanofi’s Indian ...

Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2025 First Quarter 2025 Total revenue increased ...

Dr Reddy’s & Sanofi Healthcare expand partnership to unveil Beyfortus, a novel drug to prevent RSV in India: Our Bureau, Bengaluru Tuesday, April 29, 2025, 12:15 Hrs [IST] Dr Re ...

Unchanged Outlook 2025 - Unchanged * The strategic portfolio includes Sobi's medicines Altuvoct, Aspaveli/Empaveli, Doptelet, Gamifant, Vonjo and Zynlonta, and royalty on Sanofi's sales of Altuviiio ...

Dr. Reddy’s Laboratories will expand its partnership with Sanofi Healthcare India (SHIPL) by launching the latter’s novel drug Beyfortus (nirsevimab) in India.

Dr Reddy’s and Sanofi partner to launch Beyfortus, a novel drug to prevent respiratory syncytial virus in infants.

Under the agreement, Dr Reddy's will have exclusive rights from SHIPL to promote and distribute Beyfortus within the country ...

Under the arrangement, Dr Reddy's will have exclusive rights from Sanofi to promote and distribute Beyfortus in India.